Rani Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results; Provides Corporate Update

March 26, 2026 - 19:52

Rani Therapeutics has unveiled a significant strategic collaboration and provided updates on its innovative oral drug delivery technology. The company has entered into a partnership with Chugai Pharmaceutical Co., potentially worth up to $1.085 billion, to develop and commercialize multiple high-value therapeutics using Rani's proprietary platform. Concurrently, Rani bolstered its financial position with a $60.3 million oversubscribed private placement, attracting investment from leading life science firms.

On the scientific front, Rani reported promising preclinical data for its flagship RaniPill® technology. The data demonstrated the successful oral delivery of semaglutide, a widely used GLP-1 receptor agonist, achieving systemic exposure comparable to subcutaneous injection. This milestone highlights the platform's potential to transform injectable biologics into convenient oral medications.

Furthermore, the company presented preclinical results for RT-114, a novel bispecific GLP-1/GLP-2 dual agonist candidate. The data indicated that oral delivery via the RaniPill achieved bioequivalence to subcutaneous administration, supporting its continued development. These advancements underscore Rani's progress in creating a new paradigm for patient-friendly, needle-free treatment options for chronic diseases. The company is focusing its resources on advancing its key pipeline programs toward clinical development.